Some investors asked on the investor interaction platform: can the company’s plasma gelatin be used to treat the wounded in the battlefield!
Baotou Dongbao Bio-Tech Co.Ltd(300239) ( Baotou Dongbao Bio-Tech Co.Ltd(300239) . SZ) said on the investor interaction platform on February 28 that gelatin in the second part of the company’s pharmacopoeia can be used as raw material in the field of colloidal plasma substitutes. The main application products include succinyl gelatin injection. This kind of injection can be used as colloidal volume supplement, blood dilution, cardiopulmonary bypass (cardiopulmonary machine, artificial kidney) Prevent possible indications such as hypotension after spinal cord or epidural anesthesia. At present, the gelatin in the second part of the company’s pharmacopoeia has the production capacity. It is the first national enterprise to realize this technological breakthrough, which further establishes the company’s leading position in the field of collagen application. At present, the registration and activation of Association review is being carried out. For details, you can log in to the drug review center of the State Drug Administration https://www.cde.org.cn./ see.
